Liaoning Chengda BiotechnologyLtd Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 5/6
Liaoning Chengda BiotechnologyLtd has a total shareholder equity of CN¥9.5B and total debt of CN¥5.1M, which brings its debt-to-equity ratio to 0.05%. Its total assets and total liabilities are CN¥10.0B and CN¥484.0M respectively. Liaoning Chengda BiotechnologyLtd's EBIT is CN¥402.1M making its interest coverage ratio -12.9. It has cash and short-term investments of CN¥5.4B.
Anahtar bilgiler
0.05%
Borç/özkaynak oranı
CN¥5.08m
Borç
| Faiz karşılama oranı | -12.9x |
| Nakit | CN¥5.36b |
| Eşitlik | CN¥9.55b |
| Toplam yükümlülükler | CN¥483.99m |
| Toplam varlıklar | CN¥10.03b |
Son finansal sağlık güncellemeleri
Güncelleme yok
Recent updates
Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: 688739's short term assets (CN¥7.1B) exceed its short term liabilities (CN¥379.3M).
Uzun Vadeli Yükümlülükler: 688739's short term assets (CN¥7.1B) exceed its long term liabilities (CN¥104.7M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: 688739 has more cash than its total debt.
Borcun Azaltılması: 688739's debt to equity ratio has increased from 0% to 0.05% over the past 5 years.
Borç Kapsamı: 688739's debt is well covered by operating cash flow (10346.3%).
Faiz Kapsamı: 688739 earns more interest than it pays, so coverage of interest payments is not a concern.